icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
43X1VMTwxbDLeBFp
Listen
